Use App
Trending
News
Earnings
All
DIA
0.16%
SPY
0.12%
QQQ
0.06%
Trending
ADBE
5.81%
META
0.26%
XOVR
1.99%
GOOGL
0.35%
DRAM
2.04%
AAL
0.20%
MSFT
0.65%
AMD
0.76%
RKLB
6.77%
NASA
3.97%
ADBE
5.81%
META
0.26%
XOVR
1.99%
GOOGL
0.35%
DRAM
2.04%
AAL
0.20%
MSFT
0.65%
AMD
0.76%
RKLB
6.77%
NASA
3.97%
home
Symbol
AZN
news
AZN
AstraZeneca PLC
$182.28
$3.32
(1.85%)
Today
·
Closed $182.28
$1.11
(0.61%)
After Hours
Updated:
07:57 PM EDT
1
8
,
8
2
2
1
8
,
8
2
2
Reported Earnings
Apr 29
Mkt Cap
$282.69B
Vol
1.75M
Full Chart
Fundamentals
Mkt Cap
$282.69B
Volume
-
52W High
$212.71
52W Low
$137.23
PE Ratio
27.20
Avg. Volume
1.8M
EPS (Annual)
$6.60
P/B
5.97
Rev/Employee
$611,227.89
Earnings
Apr 29
64
Bullish Sentiment
How do you feel about AZN?
Bullish
Bearish
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.
Zacks
Share to Feed
More News
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Zacks
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
Full Article
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
<
1
2
...
>
Advertisement
|
Remove ads.
Latest AZN News
View
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
Zacks
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Zacks
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
Zacks
Loading...
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile